chrisvoncsefalvay/vaers-outcomes huggingface dataset:
itchy eyes; sinus pressure; itchy ears; Also experienced headache; 3hours after the injection had fever running at around 101F for the first couple of days/now running at 99.4F-99.6F for 2 weeks; This spontaneous case was reported by a consumer and describes the occurrence of EYE PRURITUS (itchy eyes), PARANASAL SINUS DISCOMFORT (sinus pressure), PRURITUS (itchy ears), HEADACHE (Also experienced headache) and PYREXIA (3hours after the injection had fever running at around 101F for the first couple of days/now running at 99.4F-99.6F for 2 weeks) in a 32-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Hashimoto's disease and Immunocompromised.    On 30-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 30-Jul-2021, the patient experienced PYREXIA (3hours after the injection had fever running at around 101F for the first couple of days/now running at 99.4F-99.6F for 2 weeks). On an unknown date, the patient experienced EYE PRURITUS (itchy eyes), PARANASAL SINUS DISCOMFORT (sinus pressure), PRURITUS (itchy ears) and HEADACHE (Also experienced headache). At the time of the report, EYE PRURITUS (itchy eyes), PARANASAL SINUS DISCOMFORT (sinus pressure), PRURITUS (itchy ears), HEADACHE (Also experienced headache) and PYREXIA (3hours after the injection had fever running at around 101F for the first couple of days/now running at 99.4F-99.6F for 2 weeks) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 30-Jul-2021, Body temperature: 101f (High) Fever. On 01-Aug-2021, Body temperature: 101f (High) Fever. In August 2021, Body temperature: 99.4f-99.6f (High) Fever for 2 weeks.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications reported.  Treatment information not reported.
Initial report received from a health care provider on 23 August 2007. A female adolescent patient received an injection of Menactra and experienced arthralgia for three weeks following vaccination. The reporter provided no additional information and the patient's recovery status had not been reported. Follow-up information received on 21 September 2007 from a health care professional. A 14-year-old female patient had received a first dose, intramuscular injection of Menactra, lot number U2331AA; and a first dose, intramuscular injection of Havrix 720, manufacturer GSK, lot number AHAVB184AA; on 26 July 2007. There was no illness at the time of vaccination. The onset of the adverse event was the following day. The patient was subsequently diagnosed with polyarticular inflammation and follow-up was by a pediatric rheumatologist. C-reactive protein was 8.17 to 31.7. Updated recovery status was not provided. Follow-up information was received from a health care professional on 25 October 2007. SERIOUSNESS CRITERIA OTHER - MEDICALLY SIGNIFICANT The reporting physician noted that "JRA not related to shot". Diagnosis was updated to juvenile rheumatoid arthritis (JRA) and the case was determined to be serious. No additional information was provided.
Have been 2 years post menopause.  Full hormonal/menstrual cycle has come back.
Raised red slightly itchy rash from top of neck to breasts on entire chest; Raised red slightly itchy rash from top of neck to breasts on entire chest; Raised red slightly itchy rash from top of neck to breasts on entire chest; body aches; tired; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old non pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 17Mar2021 at 14:30 (at the age of 48-years-old), as a single dose for COVID-19 immunisation. Medical history included COVID-19 positive prior to vaccination. It was reported that the patient had no known allergies. The patient had not received any medications within 2 weeks of vaccination. The patient did not receive any other vaccines within four weeks, prior to the COVID vaccine. Since the vaccination, the patient had not been tested for COVID-19. On 19Mar2021 at 06:00, the patient experienced raised red, slightly itchy rash from top of neck to breasts on entire chest, body aches and tiredness. The patient did not receive any treatment for the events. The events did not result in a visit to the doctor or other healthcare professional office/clinic. The clinical outcome of raised rash, red rash, itchy rash, general body pain and tiredness was resolved on an unknown date in Mar2021. No follow-up attempts are needed. Information about lot/ batch number cannot be obtained.
Vaccine dose at 12 Years of age/Dose of the Moderna Covid19 vaccine was administrated to a boy of 12 years of age; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Vaccine dose at 12 Years of age/Dose of the Moderna Covid19 vaccine was administrated to a boy of 12 years of age) in a 12-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007D21A) for COVID-19 vaccination.     No Medical History information was reported.    On 17-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Vaccine dose at 12 Years of age/Dose of the Moderna Covid19 vaccine was administrated to a boy of 12 years of age). At the time of the report, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Vaccine dose at 12 Years of age/Dose of the Moderna Covid19 vaccine was administrated to a boy of 12 years of age) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant information was not provided. Treatment information was not provided.  Patient after vaccination stayed for 30 minutes and there were no incidents.   Most recent FOLLOW-UP information incorporated above includes: On 17-Jul-2021: Reporter information was updated. On 17-Jul-2021: Non-significant Follow up received - Reporter email address updated
This spontaneous report as received from a nurse refers to a 32 year old patient of unknown gender. Medical history and concurrent conditions were not reported. On 09-JUL-2014, the patient was vaccinated (Oka-Merck) PROQUAD, 0.5 ml, subcutaneous. Lot number and expiration date were not reported. No co-suspect and concomitant therapies were reported. The nurse reported that a 32 year old patient received a dose of (Oka-Merck) PROQUAD (on 09-JUL-2014). No symptoms reported. Additional information has been requested.
She started with a weird swelling in her throat, nasal congestion, runny nose, headache, exhaustion, fever for 2-3 days. All her other symptoms are still lingering except the fever. She is on day 8 or 9 of covid. The doctor initially thought she might have strep so they put her on amoxicillin and Bromfed Dm for cough.
Pt received vaccine at our office on 1/5/09.  On 1/6/09 pt started with redness, swelling, hot to touch with pain, some itching at the vaccine site.  Went to urgent care on 1/7/09 - was prescribed Cefalaxen 250 mg qid x 10 days.  Pt here today 1/9/09 - doing better.
PT 8 days post vax began developing rash on upper arms, spreading down arms. No lesions on any other body part. Rash maculopapular becoming vesicular, numerous lesions back upper arms and pustules do not look like Vaccinia. Increased pruritus.  A follow up report received 6/4/2003 adds: (Pt) was followed by a dermatologist and found the rash was not due to smallpox vaccine. A biopsy of the lesion was done and found to not be smallpox related.
The third dose of the Pfizer vaccine for Covid-19; Feel a torable pain in the left leg at the bottom/leg hurts; Leg was swollen; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non-HCP) from medical information team. The reporter is the patient. A 64-year-old female patient received BNT162B2, administered in arm left, on 21Nov2021 at 10:30 (Batch/Lot number: unknown) at the age of 64 years as dose 3 (booster), single for covid-19 immunization. The patient's medical history and concomitant medications were not reported. Patient previously received first and second dose of Bnt162b2, on unspecified dates for COVID-19 immunization. On 21Nov2021 10:30, patient experienced the third dose of the Pfizer vaccine for covid-19, Feel a torable pain in the left leg at the bottom/leg hurts, on an unspecified date in nov2021 Leg was swollen. Therapeutic measures were taken as a result of pain in extremity, peripheral swelling. The outcome of all events was not recovered the third dose of the Pfizer vaccine for covid-19 was unknown.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
Information has been received from a registered nurse (R.N.) concerning a 43-month-old female who on 13-OCT-2003 was vaccinated subcutaneously in the right arm with a dose of Varivax (lot# 645171/0330N). On 31-MAY-2006 the patient developed a rash that progressed with small papules on chest, abdomen, stomach and two on her buttock and a central vesicle. It was noted that several of her papules were larger ones (3-4 mm). It was unspecified if medical attention had been sought. No outcome was reported. Additional information has been requested.
This spontaneous report as received from a healthcare worker refers to an unspecified number of patients of unknown age and gender. There was no information about the patients' concurrent conditions, concomitant medications and medical histories reported. On an unknown dates between 02-FEB-2016 and 02-APR-2016, the patients were vaccinated with an improperly stored doses of VARIVAX (lot# K020761 with an expiration date 31-OCT-2016; lot# L037560 with and expiration date 29-SEP-2017, lot# K010336 with an expiration date 22-JUL-2016; dose, anatomical location and route of administration were not reported). It was also reported that an improperly stored sterile diluent (lot# K023007 with expiration date 24-SEP-2017, lot# L017417 with expiration date 02-FEB-2018, lot# L015432 with expiration date 24-JAN-2018, lot# reported as L03221 with unspecified expiration date; dose and route of administration were not reported) was used. No adverse events were reported. Temperature was 49.3 Fahrenheit degrees (F) for 48 hours, 31.2 F for 16 hours and 16.5 F for 2400 hours. There was no previous temperature excursion and no data logger was involved. Lot # L03221 had been verified to be an invalid lot # for sterile diluent. This is one of several reports received from the same reporter. Additional information has been requested.
COVID arm, hard to lift; COVID arm, hard to lift; Feels like a sunburn; Sore arm; This spontaneous case was reported by a nurse and describes the occurrence of VACCINATION SITE REACTION (COVID arm, hard to lift), RASH ERYTHEMATOUS (Feels like a sunburn), PAIN IN EXTREMITY (Sore arm) and LIMB DISCOMFORT (COVID arm, hard to lift) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 05-May-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE REACTION (COVID arm, hard to lift), RASH ERYTHEMATOUS (Feels like a sunburn), PAIN IN EXTREMITY (Sore arm) and LIMB DISCOMFORT (COVID arm, hard to lift). The patient was treated with SULFAMETHOXAZOLE, TRIMETHOPRIM (BACTRIM) at a dose of 1 dosage form. At the time of the report, VACCINATION SITE REACTION (COVID arm, hard to lift), RASH ERYTHEMATOUS (Feels like a sunburn), PAIN IN EXTREMITY (Sore arm) and LIMB DISCOMFORT (COVID arm, hard to lift) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.    This case was linked to MOD21-090237, US-MODERNATX, INC.-MOD-2021-128176, US-MODERNATX, INC.-MOD-2021-128305, US-MODERNATX, INC.-MOD-2021-128576, US-MODERNATX, INC.-MOD-2021-128643, US-MODERNATX, INC.-MOD-2021-128649, US-MODERNATX, INC.-MOD-2021-128643 (E2B Linked Report).; Sender's Comments:  MOD21-090237: US-MODERNATX, INC.-MOD-2021-128176: US-MODERNATX, INC.-MOD-2021-128305: US-MODERNATX, INC.-MOD-2021-128576: US-MODERNATX, INC.-MOD-2021-128643: US-MODERNATX, INC.-MOD-2021-128649: US-MODERNATX, INC.-MOD-2021-128643:
Patient reported that her lest arm was swollen. she went to the doctor and was prescribed Motrin 600mg and Benadryl 25mg
Pt received Moderna for the first two primary doses. Third dose was given on 2/17/23. This dose was Pfizer.
tiredness; felt sleepy; This is a spontaneous report from a contactable consumer (patient). A 60-year-old female patient received bnt162b2 (BNT162B2, Formulation: Solution for injection), dose 1 via an unspecified route of administration, administered in Arm Left on 06Jun2021 (Batch/Lot Number: EW0180) as DOSE 1, SINGLE for covid-19 immunisation. The patient's medical history and concomitant medications were not reported. The patients had the first dose Pfizer Covid Vaccine on 06Jun201 at 1200Had a little bit of tiredness and sleepiness: The caller states she had the first dose Pfizer Covid Vaccine on 06Jun201 at 1200 and this started the next morning, 07Jun2021. It started in less than 24 hours of receiving the first dose Pfizer Covid Vaccine, had a little tiredness and was more sleepy, liked to sleep. This lasted maybe 3 or 4 days. She recovered with lasting effects. The outcome of the events was recovered in Jun2021.
Extreme lethargy, swelling of lymph nodes (neck, armpits), bleeding from mucus membranes
A week or so after the vaccine the back of knee began hurting. It hurts a lot when I walk. My doctor referred me to physical therapy and an orthopedic doctor. He says my bones are fine but it is my tendons that are suffering. However, he has no explanation as to why I'm having issues with my tendons. My physical therapy will start in the first week of June and I have been doing the advised stretches from home twice daily until I begin physical therapy.
THE PATIENT WAS GIVEN THE VACCIN: PFIZER , 0.3ML , THE 4TH DOSE ,  HE SEEMED OK AFTER 15 MINUTES SUPERVISION,  NO ADVERSE EVENTS OR SYMPTOMS  WAS NOTICED, AND HIS DR WAS NOTIFIED AS WELL.
This spontaneous report as received from a other health professional refers to a patient of unknown age. On 22-OCT-2018 the patient was vaccinated with ZOSTAVAX lot # N021172, intramuscular for prophylaxis. Other suspect therapies included sterile diluent (STERILE DILUENT). On an unknown date the patient experienced incorrect route of drug administration and no adverse event. The outcome of incorrect route of drug administration and no adverse event is unknown.
This spontaneous report as received from a pharmacist via company representative, concerning to a 64 years old, female patient. In October 2013, patient was vaccinated with a dose of ZOSTAVAX. (Route, dose number, lot and expiration date not provided). On an unspecified date, pharmacist reported that the patient developed a rash around the injection site. (No timeline was given as to how soon after receiving the vaccine that the rash appeared). The patient sought medical attention (office visit). At the time of the report the patient was recovered and the causality for the rash was unknown. Additional information has been requested.
injection site almost exploded with skin peeling; Vaccination site bleeding; Vaccination site bruising; This spontaneous case was reported by a consumer and describes the occurrence of SKIN EXFOLIATION (injection site almost exploded with skin peeling), VACCINATION SITE HAEMORRHAGE (Vaccination site bleeding) and VACCINATION SITE BRUISING (Vaccination site bruising) in a 72-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026LJ01) for COVID-19 vaccination.     No medical history was provided by reporter.     On 29-Jan-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Feb-2021, the patient experienced VACCINATION SITE HAEMORRHAGE (Vaccination site bleeding) and VACCINATION SITE BRUISING (Vaccination site bruising). On an unknown date, the patient experienced SKIN EXFOLIATION (injection site almost exploded with skin peeling). At the time of the report, SKIN EXFOLIATION (injection site almost exploded with skin peeling), VACCINATION SITE HAEMORRHAGE (Vaccination site bleeding) and VACCINATION SITE BRUISING (Vaccination site bruising) outcome was unknown. Not Provided          No concomitant medication were provided by reporter  The events were treated with atopical creams and ointments on the injection site.
Fever, body aches, back pain, cough, soreness at the injection site 12/30/2020 and 12/31/2020.
REPORTED THAT DURING THE EVENING OF THE INJECTION SHE EXPERIENCED RAPID HEART RATE AND SHORTNESS OF BREATH.  THE NEXT DAY SHE EXPERIENCED RAPID HEART RATE, SWEATS, SHORTNESS OF BREATH, FEVER, PAIN AT INJECTION SITE AND ARM, KNOT UNDER ARM, NUMB FINGERS ON SAME SIDE, AND FATIGUE.
BUD date 04/07/2022 administered on 4/11/2022. Pfizer could not provide stability data beyond 04/09/2022 and recommended revaccination
lymph nodes are swollen in both armpits; injection sites a little swollen and itching really bad; injection sites a little swollen and itching really bad; This is a spontaneous report received from contactable reporter(s) (Other HCP) from medical information team.  A 52-year-old female patient received pneumococcal 20-val conj vac (dipht crm197 protein) (PREVNAR 20), on 05Sep2023 as dose 1, 0.5ml single (Lot number: GT0538, Expiration Date: Oct2024) at the age of 52 years intramuscular, in right deltoid for immunisation. The patient's relevant medical history included: "Hypertension" (unspecified if ongoing), notes: Hypertension takes medication for high blood pressure. Has been under this doctors care since 2021, unknown when diagnosed; "IBS" (unspecified if ongoing), notes: IBS takes medication; "Sleep apnea", start date: 2019 (unspecified if ongoing), notes: Sleep apnea takes medication; "Diabetes", start date: 2022 (unspecified if ongoing), notes: Diabetes takes medication. Concomitant medication(s) included: SHINGRIX intramuscular taken for immunisation, on 05Sep2023 as dose 1, 0.5ml single. The following information was reported: VACCINATION SITE SWELLING (non-serious), VACCINATION SITE PRURITUS (non-serious) all with onset 10Sep2023, outcome "unknown" and all described as "injection sites a little swollen and itching really bad"; LYMPHADENOPATHY (non-serious), outcome "unknown", described as "lymph nodes are swollen in both armpits". The events "injection sites a little swollen and itching really bad" and "lymph nodes are swollen in both armpits" required physician office visit. Additional information: The patient had no prior vaccinations within 4 weeks, no relevant family history. The doctor responded with the same response from previous patient of PRIVACY a few times a day, take Zyrtec, Claritin, or Allegra for itching and it can take up to 2 weeks to resolve and if getting worse to contact them. Looks like patient hasn't seen the message yet.
RN 1, Reconstituted newly opened Pfizer vial with 0.8ML versus the 1.8ml NS.  Noted when second RN 2 noticed how little was in the Pfizer vial.  When RN 2 asked RN1, RN 1 realized her error.   (Boyfriend of staff member) No symptoms during the 15min wait time.  Called him 1 hour later, denied symptoms instructed him to call his PCP and indicate he received  an incorrect amount.  Pharmacy working to determine how much recipient received.  Recipient, notified us that his Doc wanted to know if we knew how much of the vaccine he reived. Pharmacy is working to determine this.
I had the PREVNAR 13 shot as recommended by the MD for age over 65. My arm became extremely swollen where the shot was given. This didn't resolve for several days and I had to take multiple doses of BENADRYL.
Left leg with DTaP and MMR 6/30. Patient had a few other scattered, infected papules on body (impetigo). Patient presented 7/2/04 with 18cmx12cm, red, hot, and indurated cellulitis and temperature 100 degrees F.  Nurse follow up on 07/23/04 states: "contact dermatitis of left leg."
Pt experienced seizures on the morning of 1/23/2019. To my knowledge, he had a total of 5 seizures on that day. He had 4 in the morning and one in the evening after he was transported to Hospital.
This case is part of 2 cluster cases and is linked to case number 2013-09010 with same reporter, similar events after receiving ADACEL (lot number: C4432AB) and MENACTRA (lot number: U4648AA). Initial report received from a healthcare professional on 16 August 2013. A male patient, whose age at the time of event was not reported, had received intramuscular first dose of ADACEL vaccine (batch number: C4432AB) in the left deltoid and intramuscular first dose of MENACTRA vaccine (batch number: U4648AA, side: Right, anatomicl site of vaccination was not reported) on 14 August 2013. The patient had no known drug allergies or illness at the time of vaccination. The patient's concomitant medications were not reported. On 16 August 2013, 2 days after receiving ADACEL and MENACTRA, the patient developed reaction of redness and swelling at injection site at left deltoid. The corrective treatments and laboratory investigations were not reported. The patient had recovered from the events on an unspecified date. Follow up information received from a healthcare professional on 12 November 2013. The patient complained of pain in left groin hip area at the time of vaccination. The patient was 11 year old at the time of event. The patient had received ADACEl vaccine in left arm and MENACTRA vaccine in right arm. At the time of this report, the cessation date was unknown. Documents held by sender: none.
right axillary lymphadenopathy, fever for 7 days (low grade), fatigue, lower leg pain
child had fever of 101, lethargy, and stomach symptoms (nausea/vomiting)
Pt recvd 2 series of Recombivax & had a neg titer; recvd 2 booster doses of Hep B & still had a neg titer;
Patient is 24-years old female who reports finding out that she was pregnant on 2 August.  She reports dating by Ultrasound the fetus was 7 weeks (9 August 04) and she got her anthrax vaccination on the 25th of June.  Her calculated date of conception would be the 16th or 17th of June.
Pt. develop reaction to 1st dose of covid-19 vaccine.  Symptoms described as having nausea and tiredness.  Pt. works outside in park, verbalizes having plenty of fluids and meals eaten prior to vaccination.  Pt. currently of medications: Anxiety, buspirone and lexipro.  Pt. verbalizes feeling better, no hospital care provided.  V/S 182/91, 103 P, 99 O2.
Swelling and soreness at injection site, warmth to touch. Knot at injection site developed several hours after vaccination. Initially about the size of a baseball then decreased to golf ball size the following day.
She had significant redness and swelling.  LUE: 10x5.5 cm irregular area  RUE:  3x5 cm  MD marked borders and advised to monitor for increasing redness, swelling, or pain and to monitor for fever.  Treated with abx for presumed cellulitis
Migraines, severe pain in arms and legs, stabbing abdominal pain, diarrhea, double vision, dizziness, nausea, weakness in left arm.
At school my son had a powder chemical substance, that I do believe to be a powdered vaccine of some kind put in his face. He broke out in a rash that cause his throat to burn, his entire upper body broke out. His head swell up on the left side.